Memorial Sloan Kettering Cancer Center: Osteosarcoma trials
The registry lists 12 Osteosarcoma studies with Memorial Sloan Kettering Cancer Center as lead sponsor. 3 are open to participants now and 1 have results posted.
Phase 1 1Phase 2 6No phase 5(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With OsteosarcomaRecruitingNCT07477457Phase 2
- Expanded Access Use of L-MTP-PE for the Treatment of OsteosarcomaAvailableNCT04571229
- Assessment of Healing and Function After Reconstruction Surgery for Bone SarcomasRecruitingNCT03442465
- Phase II Study of Chemotherapy and Pamidronate for the Treatment of Newly Diagnosed OsteosarcomaCompletedNCT00586846Phase 2Results posted
- Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent OsteosarcomaActive, not recruitingNCT02502786Phase 2
- Detection of Circulating Osteosarcoma Tumor Cells in the Blood of Patients Using the Polymerase Chain ReactionCompletedNCT00588510
- Chemotherapy Resistance in Osteogenic Sarcoma and Other Solid TumorsActive, not recruitingNCT00580385Not applicable
- Cytogenetic and Molecular Genetic Studies in Bone SarcomasCompletedNCT00579930
- Methotrexate, Trimetrexate Glucuronate, and Leucovorin in Treating Patients With Refractory or Recurrent OsteosarcomaCompletedNCT00119301Phase 1
- Ecteinascidin 743 in Treating Patients With Previously Treated Metastatic OsteosarcomaCompletedNCT00005625Phase 2
- Trastuzumab in Treating Patients With Recurrent OsteosarcomaCompletedNCT00005033Phase 2
- Combination Chemotherapy and Surgery in Treating Patients With Newly Diagnosed Metastatic OsteosarcomaCompletedNCT00003776Phase 2